EXOZ

+ Watchlist + Portfolio

eXoZymes Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $6.40
52-Week Range: $4.35 – $18.40
Market Cap: $65.34M
P/E (TTM): —
EPS (TTM): -1.20
Dividend Yield: —

Advanced Metrics

Price/Book: 17.87
PEG Ratio: —
Return on Equity: -187.16%
Return on Assets: -74.74%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 3.81
Debt/Equity: 0.30
Total Debt: $1.09M
Free Cash Flow: $-4.09M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $54.83M

EXOZ Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$376.68K	$527.48K	$1.87M	$3.71M
Selling, General & Admin	$984.58K	$1.34M	$4.06M	$6.01M
Operating Expenses	$1.33M	$1.80M	$5.93M	$9.72M
Operating Income	-$1.33M	-$1.80M	-$5.93M	-$9.72M
EBITDA	-$1.18M	-$1.60M	-$5.66M	-$9.43M
Pretax Income	-$1.33M	-$2.00M	-$5.86M	-$9.26M
Income Tax	$63.56K	$42.27K	$0.00	-$105.20K
Net Income	-$1.40M	-$2.04M	-$5.86M	-$9.16M
Diluted EPS	-0.17	-0.25	-0.89	-1.09
Diluted Shares	8.13M	8.13M	6.56M	8.38M

EXOZ Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$558.57K	$66.53K	$9.72M	$3.04M
Receivables	$809.53K	$882.32K	$737.28K	$517.36K
Current Assets	$1.47M	$1.21M	$10.82M	$3.94M
Total Assets	$2.69M	$3.56M	$13.03M	$5.97M
Current Liabilities	$634.36K	$2.42M	$1.33M	$1.57M
Total Debt	$608.77K	$1.61M	$1.39M	$1.24M
Total Liabilities	$1.31M	$3.94M	$2.61M	$2.57M
Retained Earnings	-$4.05M	-$6.08M	-$11.95M	-$21.10M
Shareholders' Equity	$1.37M	-$384.32K	$10.42M	$3.40M
Working Capital	$834.88K	-$1.20M	$9.49M	$2.37M

EXOZ Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$1.26M	-$1.18M	-$8.51M	-$6.50M
Capital Expenditure	-$185.98K	-$288.71K	-$396.45K	-$169.92K
Free Cash Flow	-$1.44M	-$1.47M	-$8.90M	-$6.67M
Depreciation & Amortisation	$147.75K	$196.94K	$267.38K	$287.96K
Stock-Based Compensation	$216.50K	$281.54K	$1.13M	$1.99M
Investing Cash Flow	-$87.21K	-$311.17K	-$359.22K	-$150.22K
Financing Cash Flow	$1.36M	$1.00M	$18.52M	-$27.71K
Net Change in Cash	$10.76K	-$492.04K	$9.65M	-$6.68M

EXOZ Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$575.02K	$802.99K	$1.22M	$1.11M	$1.12M
Selling, General & Admin	$1.38M	$1.75M	$1.31M	$1.58M	$1.27M
Operating Expenses	$1.95M	$2.55M	$2.52M	$2.70M	$2.39M
Operating Income	-$1.95M	-$2.55M	-$2.52M	-$2.70M	-$2.39M
EBITDA	-$1.88M	-$2.48M	-$2.45M	-$2.62M	-$2.31M
Pretax Income	-$1.86M	-$2.36M	-$2.29M	-$2.76M	-$2.37M
Income Tax	$0.00	$0.00	$0.00	-$105.20K	$0.00
Net Income	-$1.86M	-$2.36M	-$2.29M	-$2.66M	-$2.37M
Diluted EPS	-0.22	-0.28	-0.27	—	-0.28
Diluted Shares	8.37M	8.38M	8.39M	—	8.46M

EXOZ Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$8.51M	$6.99M	$5.10M	$3.04M	$1.44M
Receivables	$595.16K	$257.75K	$302.64K	$517.36K	$302.86K
Current Assets	$9.42M	$7.53M	$5.61M	$3.94M	$2.09M
Total Assets	$11.53M	$9.68M	$7.72M	$5.97M	$4.02M
Current Liabilities	$1.44M	$1.22M	$1.24M	$1.57M	$1.58M
Total Debt	$1.33M	$1.39M	$1.32M	$1.24M	$1.16M
Total Liabilities	$2.64M	$2.44M	$2.34M	$2.57M	$2.49M
Retained Earnings	-$13.80M	-$16.16M	-$18.45M	-$21.10M	-$23.47M
Shareholders' Equity	$8.88M	$7.24M	$5.37M	$3.40M	$1.53M
Working Capital	$7.97M	$6.31M	$4.37M	$2.37M	$507.58K

EXOZ Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$1.13M	-$1.54M	-$1.86M	-$1.97M	-$1.52M
Capital Expenditure	-$31.05K	-$50.57K	-$13.31K	-$74.99K	-$57.60K
Free Cash Flow	-$1.16M	-$1.59M	-$1.87M	-$2.05M	-$1.58M
Depreciation & Amortisation	$70.50K	$72.26K	$71.60K	$73.60K	$74.15K
Stock-Based Compensation	$317.28K	$567.25K	$425.71K	$677.87K	$501.10K
Investing Cash Flow	-$31.05K	-$30.87K	-$13.31K	-$74.99K	-$57.60K
Financing Cash Flow	-$43.25K	$43.25K	-$17.16K	-$10.55K	-$12.74K
Net Change in Cash	-$1.21M	-$1.53M	-$1.89M	-$2.06M	-$1.59M

Market Snapshot

About

eXoZymes Inc. is a biotechnology company developing novel enzyme therapies for rare genetic diseases and other serious medical conditions. The company's therapeutic approach focuses on creating enzyme replacement therapies and enzyme-based treatments that address underlying disease mechanisms. eXoZymes is advancing a pipeline of product candidates targeting metabolic disorders, genetic diseases, and other conditions where enzyme deficiencies or dysfunctions play a critical role. The company conducts research and development activities aimed at bringing innovative biologic therapies to patients with limited treatment options.